Q3 EPS Estimates for Alpha Cognition Decreased by Analyst

Key Points

• HC Wainwright cut its Q3 2026 EPS estimate for Alpha Cognition to a loss of $0.33 per share from a previous loss estimate of $0.20, while maintaining a Buy rating and $20 price target.
• Alpha Cognition reported a quarterly loss of $0.40 per share, slightly missing the $0.39 consensus estimate, but revenue of $6.0 million exceeded expectations of $4.38 million.
• Analyst sentiment remains positive, with four Buy ratings and a consensus price target of $17.25, compared with the stock’s opening price of $8.57.

Alpha Cognition Inc. (NASDAQ:ACOG - Free Report) - Analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for shares of Alpha Cognition in a research note issued to investors on Monday, August 17th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.33) per share for the quarter, down from their prior forecast of ($0.20). HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Alpha Cognition's current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Alpha Cognition's Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.33) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.31) EPS.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.01). The firm had revenue of $6.00 million during the quarter, compared to analyst estimates of $4.38 million. Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%.

Other analysts have also issued research reports about the company. Maxim Group began coverage on Alpha Cognition in a report on Friday, May 29th. They set a "buy" rating and a $12.00 price objective on the stock. Raymond James Financial began coverage on shares of Alpha Cognition in a research note on Friday, July 10th. They set an "outperform" rating and a $20.00 price target on the stock. Wall Street Zen upgraded shares of Alpha Cognition from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Craig Hallum reissued a "buy" rating and issued a $17.00 target price on shares of Alpha Cognition in a report on Friday. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Alpha Cognition presently has an average rating of "Buy" and a consensus price target of $17.25.

Alpha Cognition Price Performance

Shares of NASDAQ:ACOG opened at $8.57 on Wednesday. Alpha Cognition has a 12 month low of $4.50 and a 12 month high of $10.00. The stock has a market cap of $186.57 million, a price-to-earnings ratio of -7.79 and a beta of 2.30. The stock's 50 day moving average price is $7.85 and its 200 day moving average price is $6.57.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC bought a new position in Alpha Cognition in the 2nd quarter valued at $112,000. Marshall Wace LLP bought a new stake in shares of Alpha Cognition during the second quarter worth $600,000. Cable Car Capital LP raised its position in shares of Alpha Cognition by 68.8% during the second quarter. Cable Car Capital LP now owns 869,002 shares of the company's stock worth $8,108,000 after acquiring an additional 354,278 shares during the last quarter. Massar Capital Management LP bought a new stake in shares of Alpha Cognition during the second quarter worth $116,000. Finally, Manatuck Hill Partners LLC lifted its stake in shares of Alpha Cognition by 74.6% during the second quarter. Manatuck Hill Partners LLC now owns 117,000 shares of the company's stock valued at $1,092,000 after acquiring an additional 50,000 shares during the period.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source